Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 5, 2026—Leica Biosystems has expanded its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry assay and image analysis algorithm specifically for the TROP2 normalized membrane ratio biomarker in non-small cell lung cancer, for use as a research tool only.
June 4, 2026—Waters Corp. announced that the BD Bactec FXI culture system has received FDA 510(k) clearance.
June 3, 2026—Diazyme Laboratories has acquired Carolina Liquid Chemistries Corp., an FDA-registered manufacturer and reseller of chemistry systems and reagents.
June 2, 2026—Sysmex America has introduced the XR-Series, a hematology solution designed to help laboratories deliver fast, reliable results while maintaining efficient workflows.
May 29, 2026—Leica Biosystems, Indica Labs, and Lunit are partnering to develop AI-powered image analysis algorithms.
May 28, 2026—Seegene launched its new antimicrobial resistance testing product, the Allplex MDRO assay.
May 27, 2026—Horiba has launched Yumivet, its new veterinary diagnostics brand, and introduced the Yumivet VH2500 hematology analyzer.
May 26, 2026—FujiFilm Healthcare Americas has announced a strategic partnership with mTuitive under which it will integrate mTuitive’s structured pathology reporting platform with FujiFilm’s Synapse Pathology picture archiving and communication system.
May 21, 2026—Finland’s Grundium, backed by U.S.-based health care private equity firm EW Healthcare Partners, has acquired Visiopharm, of Denmark.
May 20, 2026—Anchor Molecular launched its BCR-ABL1 control panels designed to support laboratories in monitoring the performance of the quantitative detection of BCR-ABL1 translocation mRNA transcripts.
